Selexipag i s a kind of oral highly selective prostacyclin （IP）receptor agonist ，which can inhibit the contraction and proliferation of pulmonary artery smooth muscle cells. Because of its good patient compliance and high receptor affinity ，it is currently used in the treatment of pulmonary hypertension （PH）. This article reviews the mechanism of action ，pharmacokinetics/ pharmacodynamics and application of selexipag in the treatment of PH. The results show that selexipag alone or in combination with endothelin receptor antagonists and （or）phosphodiesterase inhibitors can effectively reduce the risk of worsening/death events ， delay disease progression ，and improve patients ’life quality in patients with adult pulmonary arterial hypertension （PAH）of WHO cardiac function Ⅱ-Ⅲ grade. However ，its application in children with PAH and patients with chronic thromboembolic PH needs further exploration.